|
Radiation Emergency Medical Management (REMM)
|
Resource Development
|
CDC, IOS, ASPR
|
NLM, NCI
|
This activity is to develop a comprehensive web resource and mobile app. Radiation Emergency Medical Management (REMM) is a mechanism to collect, evaluate, collate, store, and make available electronically to health care professionals immediate, up-to-date, evidence-based clinical information they would use to treat civilian patients and others affected by radiation incidents.
|
|
Radiation-Induced Immune Dysfunction Meeting
|
Meeting/ Workshop
|
ASPR
|
NIAID
|
The purpose of the workshop is to bring investigators together from the radiation biology and basic immunology fields to examine effects of radiation-induced hematopoietic injury, including natural history – early effects, recovery and residual damage.
|
|
Radiation-Induced Multi Organ Dysfunction Meeting Planning Group
|
Meeting/ Workshop
|
ASPR
|
NIAID, NCI
|
The objectives of the workshop are to 1) explore radiation-induced multi-organ injury, in particular, the connections and underlying mechanisms driving injury to affected organs; 2) assess how various treatments can ameliorate these injuries; and 3) publish a meeting report in a peer-review journal. Meeting will be held November 2-3, 2021.
|
|
Radiobiology Bioterrorism Research and Training Group (RABRAT)
|
Meeting/ Workshop
|
FDA, OS
|
NCI, NIAID
|
This activity involves monthly meetings to discuss research initiatives, funding opportunities, training, conferences, publications, and other events and information related to preparing the US Government to respond to nuclear terrorism.
|
|
Rapid Acceleration of Diagnostics Tech Program (RADx Tech)
|
Research Initiative
|
CMS, FDA, CDC, ASPR
|
NIBIB
|
To help address the COVID-19 pandemic, National Institute of Biomedical Imaging and Bioengineering (NIBIB) received $500 million to support the development of new SARS-CoV-2 virus testing technologies. The funding is part of the fourth congressional supplement (PPP Act). Additional funds ($307 mil) from Biomedical Advanced Research and Development Authority (BARDA) were transferred and an additional appropriations ($100 mil) from the fifth congressional supplement. The Rapid Acceleration of Diagnostics (RADx) Tech program is leveraging NIBIB's existing Point-of-Care Technologies Research Network (POCTRN) to accelerate the development, validation, and commercialization of innovative POC and home-based tests, as well as improvements to existing clinical laboratory methods. RADx Tech is supporting the full range of product development including technology validation, clinical translation, commercialization, and product distribution. General information about the RADx Tech https://www.nih.gov/research-training/medical-research-initiatives/radx… RADx Tech dashboard - https://www.nibib.nih.gov/covid-19/radx-initiative-dashboard
|
|
Rare Disease Day at NIH
|
Meeting/ Workshop
|
FDA
|
NCATS, NHLBI, NCI, NHGRI, NICHD, NINDS, CC
|
Rare Disease Day® takes place worldwide, typically on or near the last day of February each year, to raise awareness among policymakers and the public about rare diseases and their impact on patients’ lives. Each year, the National Center for Advancing Translational Sciences (NCATS) and the National Institutes of Health (NIH) Clinical Center sponsor Rare Disease Day at NIH as part of this global observance. Rare Disease Day at NIH aims to raise awareness about rare diseases, the people they affect, and NIH research collaborations underway to address scientific challenges and to advance new treatments. The goals of Rare Disease Day at NIH are to: demonstrate the NIH commitment to helping people with rare diseases through research; highlight NIH-supported rare diseases research and the development of diagnostics and treatments; initiate a mutually beneficial dialogue among public and private researchers, patients, patient advocates, and policymakers; exchange the latest rare diseases information with stakeholders to advance research and therapeutic efforts; put a face on rare diseases by sharing stories of patients, their families, and their communities.
|
|
rCR training to Grants Managers
|
Training Initiative
|
OASH
|
OD/OER
|
OHRP and NIH staff will discuss the responsibilities regarding human subjects protection in NIH funded research. This session will cover the fundamentals of the Common Rule including Federalwide Assurance, IRB review, and informed consent. OHRP faculty will discuss the impact of the revised Common Rule. NIH faculty will discuss NIH policies and procedures relevant to implementation of the revised Common Rule.
|
|
Reciprocal Educational and Training Partnerships between FDA/CDER and the NIH Clinical Center
|
Training Initiative
|
FDA
|
CC, NCI, NIAID, NIDCR, NIDDK, NIMH, NINDS
|
This activity is sponsored by the Clinical Pharmacology Program, Office of Clinical Research Training and Medical Education (OCRTME) at The National Institutes of Health (NIH) Clinical Center (CC). It consists of elective rotations at the Office of Clinical Pharmacology (OCP) and the Office of New Drugs (OND) of the US Food and Drug Administration's (FDA) Center for Drug Evaluation and Research. It is for NIH staff, with a primary focus on clinical fellows and research fellows, who expressed an interest in learning more about FDA regulatory sciences applicable to drug development research. Rotating fellows are mentored by FDA staff on the required elements of an Investigational New Drug (IND) application and the key elements of the FDA review process from a regulatory perspective. This program also established a mechanism for FDA scientific reviewers at the OCP to rotate at the NIH CC and to interact with members of a clinical research team, thus acquiring a better perspective on clinical research protocol implementation and the requirements of an Institutional Review Board (IRB) at the NIH.
|
|
Recognize, Assist, Include, Support and Engage (RAISE) Family Caregiving Advisory Council
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NIA
|
Federal and non-federal advisory council is charged with providing recommendations to the Secretary of Health and Human Services on effective models of both family caregiving and support to family caregivers, as well as improving coordination across federal government programs, as mandated by the Recognize, Assist, Include, Support, and Engage (RAISE) Family Caregivers Act of 2017.
|
|
Reentry Research Network
|
Committee, Work group, Advisory group, or Task Force
|
ACF, SAMHSA
|
NIDA, OD/DPCPSI/OBSSR
|
This is a subgroup that reports to the Federal Interagency Reentry Council. The purpose of this group is to bring together numerous federal agencies to make communities safer, assist those returning from prison and jail to becoming productive, tax-paying citizens, and save taxpayer dollars by lowering the direct and collateral costs of incarceration. The National Institute on Drug Abuse (NIDA) serves on the HHS Re-entry/CJ working group. Staff meets by phone monthly.
|